TOP GUIDELINES OF MBL77

For people with symptomatic disease demanding therapy, ibrutinib is often recommended according to four section III randomized clinical trials comparing ibrutinib with chlorambucil monotherapy106 and other typically applied CIT combinations, specifically FCR, bendamustine as well as rituximab and chlorambucil in addition obinutuzumab (ClbO).107–1